Australia

Clinuvel Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

First Stroke Patient Treated with Afamelanotide

Lead Product(s): Afamelanotide

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Scenesse

Highest Development Status: Phase III Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 07, 2021

Details:

The CUV801 study is evaluating the use of afamelanotide in six patients who suffered an acute stroke, with a main focus on safety monitoring following drug administration as they are admitted to hospital.

Mesoblast

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Mesoblast Completes US$110/A$138 Million Financing Led by US Strategic Investor Group

Lead Product(s): Rexlemestrocel-L

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Revascor

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $110.0 million Upfront Cash: Undisclosed

Deal Type: Financing March 02, 2021

Details:

Funds will be used in advancing manufacturing and development of rexlemestrocel-L platform to meet commercial objectives for chronic heart failure and chronic low back pain due to degenerative disc disease following the recent completion of Phase 3 trials.